Stock CYCN CYCLERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-04-26 EDT 		5-day change 1st Jan Change
2.93 USD -3.62% Intraday chart for Cyclerion Therapeutics, Inc. -16.29% -12.54%
03-05 Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Cyclerion Therapeutics, Inc. Appoints Regina Graul as President CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 74.72 103.9 74.5 28.54 8.191
Enterprise Value (EV) 1 53.74 95.26 20.54 15.16 0.6201
P/E ratio -0.61 x -1.2 x -1.3 x -0.65 x -1.49 x
Yield - - - - -
Capitalization / Revenue 16,577,637 x 45,262,757 x 18,899,815 x 17,563,618 x -
EV / Revenue 16,577,632 x 45,262,754 x 18,899,802 x 17,563,610 x -
EV / EBITDA -0.62 x -1.36 x -1.38 x -0.64 x -0.85 x
EV / FCF -1.07 x -2.9 x -3.67 x -1.15 x -0.86 x
FCF Yield -93.1% -34.5% -27.3% -86.9% -116%
Price to Book 0.77 x 1.75 x 1.55 x 2.73 x 0.73 x
Nbr of stocks (in thousands) 1,373 1,698 2,166 2,175 2,445
Reference price 2 54.40 61.20 34.40 13.12 3.350
Announcement Date 20-03-12 21-02-25 22-02-24 23-03-22 24-03-05
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - 4.507 2.296 3.942 1.625 -
EBITDA 1 -104.7 -119.8 -76.24 -53.84 -44.31 -9.582
EBIT 1 -106.2 -122.5 -78.53 -54.31 -44.37 -9.647
Operating Margin - -2,718.82% -3,420.47% -1,377.83% -2,730.58% -
Earnings before Tax (EBT) 1 -115.3 -123 -77.8 -51.65 -44.08 -12.59
Net income 1 -115.3 -123 -77.8 -51.65 -44.08 -5.263
Net margin - -2,729.27% -3,388.59% -1,310.17% -2,712.49% -
EPS 2 -148.2 -89.85 -51.18 -26.39 -20.28 -2.251
Free Cash Flow 1 -51.69 -69.58 -35.8 -20.33 -24.82 -9.518
FCF margin - -1,543.88% -1,559.31% -515.61% -1,527.11% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-11 20-03-12 21-02-25 22-02-24 23-03-22 24-03-05
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3
Net sales 1 0.348 0.533 0.711 0.306 -
EBITDA - - - - -
EBIT 1 -11.28 -14.34 -12.98 -13.43 -10.61
Operating Margin -3,242.82% -2,690.06% -1,826.16% -4,389.87% -
Earnings before Tax (EBT) 1 -11.29 -10.78 -12.98 -13.39 -10.5
Net income 1 -11.29 -10.78 -12.98 -13.39 -10.5
Net margin -3,244.25% -2,021.58% -1,825.32% -4,375.16% -
EPS 2 -5.200 -4.723 -6.000 -6.200 -4.800
Dividend per Share - - - - -
Announcement Date 21-11-09 22-02-24 22-05-04 22-08-09 22-11-03
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt - - - - - -
Net Cash position - 21 8.66 54 13.4 7.57
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -51.7 -69.6 -35.8 -20.3 -24.8 -9.52
ROE (net income / shareholders' equity) 1,212% -282% -99% -95.9% -150% -116%
ROA (Net income/ Total Assets) -1,032% -79% -32.5% -38.9% -71.7% -38.3%
Assets 1 11.17 155.7 239.2 132.9 61.52 13.73
Book Value Per Share 2 -13.40 70.80 34.90 22.20 4.800 4.560
Cash Flow per Share - 68.80 32.00 24.90 6.150 3.060
Capex 1 3.44 6.89 1.52 0.01 - -
Capex / Sales - 152.83% 66.38% 0.18% - -
Announcement Date 19-03-11 20-03-12 21-02-25 22-02-24 23-03-22 24-03-05
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CYCLERION THERAPEUTICS, INC. Stock Cyclerion Therapeutics, Inc.
-12.54% 7.44M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CYCN Stock
  4. Financials Cyclerion Therapeutics, Inc.